MXiPr

Discovery

MXiPr appeared on online research chemical markets in late 2020 with no prior description in pharmaceutical or academic literature. The National Forensic Laboratory of Slovenia performed the first formal identification in December 2020.^[2][3] It is the N-isopropyl variant of methoxetamine (MXE) — a small structural change that produces a legally distinct molecule while preserving the pharmacological core.

Forensic and pharmacological characterization

MXiPr emerged alongside MXPr and DMXE as part of a wave of MXE analogues designed to circumvent scheduling across multiple jurisdictions.^[4][5] Tanaka et al. identified it in seized products in Japan,^[2] and Irie et al. published the only pharmacological study, measuring its potency at blocking glutamate receptors and flagging it as a serious concern given its potency and unregulated availability.^[1]

Market presence

MXiPr continues to circulate in European drug markets. A harm reduction drug-checking service in Marseille detected it in a submitted pill in October 2024,^[6] and the French Addictovigilance Network has flagged it in reports on emerging ketamine analogue use patterns.^[10] Its detection in tablet form means it may be sold as or mixed with other substances.

Structural class

MXiPr belongs to the arylcyclohexylamine family — compounds built around a cyclohexane ring joined to an aromatic group and an amine. This scaffold is shared with ketamine, PCP, and methoxetamine (MXE). MXiPr is the N-isopropyl homolog of MXE, with molecular formula C₁₆H₂₃NO₂ and a molecular weight of 261.365 g/mol — the same core molecule with a branched isopropyl group on the nitrogen instead of MXE's ethyl group.

Stereochemistry

MXiPr has two mirror-image forms (R and S enantiomers), separable in the laboratory.^[11] Whether one form is more potent than the other has not been studied; for reference, S-ketamine is roughly twice as potent as R-ketamine at the same receptor target.^[12]

Mechanism of action

MXiPr blocks glutamate signaling in the brain by entering and plugging the ion channel used by NMDA receptors.^[12][4] This is the same mechanism as ketamine and PCP. Reducing glutamate activity disrupts normal sensory processing and produces the dissociative state.

The only published potency measurement places MXiPr between MXE and DMXE in blocking strength.^[1] MXE is known to also affect serotonin pathways,^[13] but whether MXiPr shares that secondary activity is unknown. inferred

Pharmacokinetics

No human pharmacokinetic data exist for MXiPr. A study using rat tissue and human liver cells identified the main metabolic pathways as breakdown of the isopropyl group, ring hydroxylation, and phase II conjugation^[14] — the resulting metabolites can be detected in urine. People with liver impairment may experience longer drug exposure and greater toxicity risk, as established for the arylcyclohexylamine class.^[12] inferred

Where it acts

NMDA blockade disrupts communication between the thalamus and cortex — the pathway that stitches sensory information into coherent experience.^[12] At lower doses, this selectively quiets inhibitory neurons, paradoxically increasing glutamate activity in the frontal brain and producing the stimulant-like lucidity reported at sub-dissociative amounts.^[7] At higher doses, more complete blockade progressively disconnects the brain from sensory input, producing immersive disconnection.

Why it matters

By disrupting the brain's error-correction signaling at these synapses, these compounds degrade the internal model of reality — at low doses perception distorts; at high doses the model collapses. Separately, ketamine research has shown new neural connections can form rapidly following this type of receptor blockade^[12] — whether MXiPr produces the same neuroplastic changes is unknown.

Toxicity

No controlled toxicity data exist for MXiPr. No lethal dose has been established in any species, and no human death attributed solely to MXiPr appears in published literature. safety citation needed

Psychological risks

NMDA antagonists can cause anxiety, paranoia, and confusion during the acute phase, particularly at higher doses or in unfamiliar settings.^[16] Working memory, decision-making, and spatial orientation are impaired during and shortly after use.

In vulnerable individuals, blocking glutamate signaling can trigger psychotic episodes — paranoia, hallucinations, and disordered thinking.^[12] The antidepressant-like properties of NMDA antagonists may attract self-medication patterns, driving escalating use frequency.^[12]

Tolerance & dependence

No published studies characterize MXiPr-specific tolerance or dependence. Tolerance builds as the brain compensates by upregulating glutamate activity; cross-tolerance with other dissociatives is expected,^[16] with community estimates placing full reset around 1.5 weeks. inferred

Physical dependence potential is moderate, inferred from ketamine and MXE — withdrawal may bring anxiety, low mood, craving, and insomnia. Psychological dependence potential is also moderate; the warm afterglow^[7] and antidepressant-like effects create meaningful reinforcement potential, and compulsive redosing has been noted in community reports.

Drug interactions

No published interaction data exist for MXiPr. All assessments are class-level inferences from the arylcyclohexylamine profile. inferred

CNS depressants — opioids, benzodiazepines, alcohol, GHB, barbiturates — are the highest-risk combination. They stack on top of MXiPr's sedative effects and can suppress breathing to a fatal degree. A fatal case involving a related compound included co-presence of morphine, oxycodone, and venlafaxine.^[8]

Serotonergic agents (MAOIs, SSRIs, SNRIs) may trigger serotonin syndrome — a life-threatening overheating and seizure response — if MXiPr shares the serotonin pathway affinity seen in MXE.^[13] The fatal case reported by Theofel et al. involved co-administration with venlafaxine, an SNRI.^[8]

Stimulants can mask sedation at higher doses, raising overdose risk, and add cardiovascular strain on top of the class-level increase in heart rate and blood pressure. Other dissociatives produce unpredictable amplification of effects through additive glutamate blockade — hazardous in individuals without tolerance.

Contraindications

No substance-specific contraindication data exist for MXiPr. All are inferred from the arylcyclohexylamine class profile. inferred

Absolute contraindications:

• History of psychotic disorders: NMDA antagonists can trigger or worsen psychotic episodes. People with schizophrenia, schizoaffective disorder, or a personal history of psychosis should avoid all NMDA antagonists.
• Concurrent MAOI use: If MXiPr has serotonin pathway affinity (unconfirmed), combination with MAOIs poses serotonin syndrome risk.

Relative contraindications:

• Heart conditions: Raised heart rate and blood pressure pose elevated risk for people with pre-existing cardiovascular disease.
• Liver impairment: MXiPr undergoes extensive liver metabolism;^[14] impaired function may prolong drug exposure and increase toxicity risk.
• Kidney or bladder conditions: Class-based concern for bladder and urinary tract damage, particularly with repeated use.
• Seizure disorders: User reports of seizures at high doses^[7] and class-level seizure threshold effects^[16] indicate elevated risk for people with epilepsy or a lowered seizure threshold.
• Pregnancy and breastfeeding: No reproductive toxicity data exist. NMDA signaling plays a critical role in developing brains; exposure during pregnancy carries theoretical risk to the developing nervous system. safety citation needed

MXiPr has been explicitly scheduled in only a few countries. Elsewhere, structural analog laws may apply depending on how its structural relationship to controlled substances — particularly PCP and ketamine — is interpreted by prosecutors.